Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
squamous cell neoplasms
MeSH D018307 - squamous cell neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009375:
Glandular and epithelial neoplasms
0 Companies
0 Drugs
Success rate
D018307:
Squamous cell neoplasms
2 Companies
2 Drugs
$
Success rate
D002291:
Papillary carcinoma
0 Companies
0 Drugs
Success rate
D002294:
Squamous cell carcinoma
18 Companies
8 Drugs
$
Success rate
D010212:
Papilloma
0 Companies
0 Drugs
Success rate
D018289:
Verrucous carcinoma
0 Companies
0 Drugs
Success rate
D049309:
Acanthoma
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Regeneron Pharmaceuticals
Cemiplimab
Libtayo
2019-06-28
$1,093.7 M
Q4/23-Q3/24
Clinical Trials
Historical Success Rate
Phase 1
74
%
55/74
Phase 2
25
%
28/110
Phase 3
17
%
7/41
Approved:
0
Overall Success rate:
3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Biolitec Pharma
TEMOPORFIN
Regeneron Pharmaceuticals
Cemiplimab
,
Cemiplimab-rwlc
,
Alfacalcidol
,
Nvb
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use